Skip to main content
. 2022 Nov 15;37(1):61–71. doi: 10.1038/s41375-022-01746-3

Fig. 2. Azacitidine and decitabine prolong survival in KMT2A-rearranged infant acute lymphoblastic leukemia xenografts.

Fig. 2

Mice injected with leukemia cells were treated with vehicle control, 2.5 mg/kg azacitidine, 5 mg/kg azacitidine or 0.5 mg/kg decitabine once daily for five days when the percentage of human CD19+ CD45+ cells reached 1% in the bone marrow. Five xenograft models were used: MLL-5, MLL-7, MLL-14, LR-iALL2 and PER-785. Left panels: Percentage of human CD19+ CD45+ cells in peripheral blood over time. Right panels: Kaplan–Meier survival curves of the treated and control mice (n = 8–10 mice/group). The gray shaded areas indicate the treatment periods. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.